Amgen

At a glance

Amgen reported 2025 revenue of $36.75B, up 10% from $33.42B in 2024. Over 4 years since 2021 ($25.98B), that is growth of about 9.1% a year. Operating margin was 24.7%, down from 29.4% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 6 insiders reported 0 open-market purchases and 9 sales ($29.3M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $20.8M by EVP, Operations Esteban Santos on Mar 2, 2026.

Amgen filed 11 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), officer or director change (3), cybersecurity incident (1) and shareholder vote results (1). The latest officer or director change was reported on Oct 27, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.

2 of the 20 investors tracked here held Amgen at the last quarter end, worth $473.7M combined. It is the largest weight for National Pension Service (Korea) (0.3% of its portfolio), followed by Bridgewater Associates (0%). Added: Bridgewater Associates.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.